208 related articles for article (PubMed ID: 36859300)
21. A single-dose study of denosumab in patients with various degrees of renal impairment.
Block GA; Bone HG; Fang L; Lee E; Padhi D
J Bone Miner Res; 2012 Jul; 27(7):1471-9. PubMed ID: 22461041
[TBL] [Abstract][Full Text] [Related]
22. Hungry bone syndrome like presentation following single-dose denosumab for hypercalcaemia secondary to sarcoidosis with IgA nephropathy.
Nachankar A; Katyal A; Bansal N; Bishnoi A
BMJ Case Rep; 2022 Jul; 15(7):. PubMed ID: 35803612
[TBL] [Abstract][Full Text] [Related]
23. Hypomagnesemia with Secondary Hypocalcemia (HSH): a Case Report.
Zhao C; Lin Y; Jiang Z
Clin Lab; 2023 Oct; 69(10):. PubMed ID: 37844054
[TBL] [Abstract][Full Text] [Related]
24. Severe Hypocalcemia due to Denosumab in Metastatic Prostate Cancer.
Muqeet Adnan M; Bhutta U; Iqbal T; AbdulMujeeb S; Haragsim L; Amer S
Case Rep Nephrol; 2014; 2014():565393. PubMed ID: 25054070
[TBL] [Abstract][Full Text] [Related]
25. [A rare cause of kidney injury: vitamin D3 intoxication].
Hutkai D; Bodor M
Orv Hetil; 2023 Nov; 164(47):1871-1876. PubMed ID: 38007710
[TBL] [Abstract][Full Text] [Related]
26. Denosumab-induced hypocalcemia in a patient with hyperthyroidism: a case report.
Park SY; Kim J; Chung HY
Osteoporos Int; 2022 Jan; 33(1):305-308. PubMed ID: 34232341
[TBL] [Abstract][Full Text] [Related]
27. Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy.
Iizumi S; Shimoi T; Nishikawa T; Kitano A; Sasada S; Shimomura A; Noguchi E; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
Intern Med; 2017 Nov; 56(21):2879-2882. PubMed ID: 28943574
[TBL] [Abstract][Full Text] [Related]
28. Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients.
Bird ST; Smith ER; Gelperin K; Jung TH; Thompson A; Kambhampati R; Lyu H; Zhao H; Zhao Y; Zhu Y; Easley O; Niak A; Wernecke M; Chillarige Y; Zemskova M; Kelman JA; Graham DJ
JAMA; 2024 Feb; 331(6):491-499. PubMed ID: 38241060
[TBL] [Abstract][Full Text] [Related]
29. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
30. Investigation of Prescription Status and Exploration of Risk Factors Related to Denosumab-Induced Hypocalcemia in Combination Therapy with 1α,25-Dihydroxy-vitamin D
Ikegami K; Saito M; Imai S; Kizaki H; Yasumuro O; Funakoshi R; Hori S
Biol Pharm Bull; 2023; 46(1):95-101. PubMed ID: 36596529
[TBL] [Abstract][Full Text] [Related]
31. Case report: Denosumab-associated acute heart failure in patients with cardiorenal insufficiency.
Xing Y; Ju S; Sun M; Xiang S
Front Endocrinol (Lausanne); 2022; 13():970571. PubMed ID: 36187135
[TBL] [Abstract][Full Text] [Related]
32. Activated vitamin D3 formulations can be safely used as concomitant medication for prevention of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis.
Saito S; Sugo Y; Tsuburai T; Kurasawa K; Nakamura T; Yoshikata H; Miyagi E; Sakakibara H
J Obstet Gynaecol Res; 2019 Apr; 45(4):908-914. PubMed ID: 30618176
[TBL] [Abstract][Full Text] [Related]
33. Low-dose cholecalciferol supplementation and dual vitamin D therapy in haemodialysis patients.
Dusilová-Sulková S; Šafránek R; Vávrová J; Horáček J; Pavlíková L; Palička V
Int Urol Nephrol; 2015 Jan; 47(1):169-76. PubMed ID: 25262147
[TBL] [Abstract][Full Text] [Related]
34. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone.
Whitson HE; Lobaugh B; Lyles KW
Bone; 2006 Oct; 39(4):954-8. PubMed ID: 16769264
[TBL] [Abstract][Full Text] [Related]
35. Denosumab-induced severe hypocalcaemia in a patient with vitamin D deficiency.
Daga N; Joseph F
BMJ Case Rep; 2020 Aug; 13(8):. PubMed ID: 32847872
[TBL] [Abstract][Full Text] [Related]
36. Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?
Tsvetov G; Amitai O; Shochat T; Shimon I; Akirov A; Diker-Cohen T
Osteoporos Int; 2020 Apr; 31(4):655-665. PubMed ID: 31838550
[TBL] [Abstract][Full Text] [Related]
37. High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis.
Ishikawa K; Nagai T; Sakamoto K; Ohara K; Eguro T; Ito H; Toyoshima Y; Kokaze A; Toyone T; Inagaki K
Ther Clin Risk Manag; 2016; 12():1831-1840. PubMed ID: 27980413
[TBL] [Abstract][Full Text] [Related]
38. A Case of Recurrent Severe Hypocalcemia with Prolonged Hospitalization and Readmissions After Single Dose of Denosumab in Metastatic Prostate Cancer Patient.
Kc O; Dahal PH; Koirala M; Kothagundla CS; Al Zaghal E; Fahed R
J Community Hosp Intern Med Perspect; 2022; 12(2):60-64. PubMed ID: 35712685
[TBL] [Abstract][Full Text] [Related]
39. Severe resistant hypocalcemia in multiple myeloma after zoledronic acid administration: a case report.
Noriega Aldave AP; Jaiswal S
J Med Case Rep; 2014 Oct; 8():353. PubMed ID: 25342294
[TBL] [Abstract][Full Text] [Related]
40. Hypocalcemic tetany associated with simultaneous administration of cimetidine and nifedipine: a case report.
Bezabih YM; Bimrew MA; Bezabhe WM
J Med Case Rep; 2023 Jul; 17(1):337. PubMed ID: 37501199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
